NO306624B1 - Rekombinant DNA-molekyl som koder for <beta>-kjeden til en IL-2 reseptor - Google Patents
Rekombinant DNA-molekyl som koder for <beta>-kjeden til en IL-2 reseptor Download PDFInfo
- Publication number
- NO306624B1 NO306624B1 NO901046A NO901046A NO306624B1 NO 306624 B1 NO306624 B1 NO 306624B1 NO 901046 A NO901046 A NO 901046A NO 901046 A NO901046 A NO 901046A NO 306624 B1 NO306624 B1 NO 306624B1
- Authority
- NO
- Norway
- Prior art keywords
- chain
- recombinant dna
- dna molecule
- receptor
- ferm
- Prior art date
Links
- 108020004511 Recombinant DNA Proteins 0.000 title claims description 22
- 102000053602 DNA Human genes 0.000 title claims description 21
- 102000010789 Interleukin-2 Receptors Human genes 0.000 title claims description 17
- 108010038453 Interleukin-2 Receptors Proteins 0.000 title claims description 16
- 210000004027 cell Anatomy 0.000 claims description 77
- 108010002350 Interleukin-2 Proteins 0.000 claims description 69
- 102000000588 Interleukin-2 Human genes 0.000 claims description 69
- 108090000623 proteins and genes Proteins 0.000 claims description 36
- 150000001413 amino acids Chemical class 0.000 claims description 30
- 230000014509 gene expression Effects 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 22
- 102000004169 proteins and genes Human genes 0.000 claims description 20
- 239000013612 plasmid Substances 0.000 claims description 19
- 108020004414 DNA Proteins 0.000 claims description 16
- 239000012634 fragment Substances 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 8
- 230000001580 bacterial effect Effects 0.000 claims description 7
- 239000013604 expression vector Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 210000004408 hybridoma Anatomy 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 6
- 108091026890 Coding region Proteins 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000002955 isolation Methods 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 230000009466 transformation Effects 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 abstract description 70
- 239000013598 vector Substances 0.000 abstract description 17
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 abstract description 12
- 108040002099 interleukin-21 receptor activity proteins Proteins 0.000 abstract 1
- 102000008640 interleukin-21 receptor activity proteins Human genes 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 description 36
- 108020003175 receptors Proteins 0.000 description 36
- 235000001014 amino acid Nutrition 0.000 description 24
- 108020004999 messenger RNA Proteins 0.000 description 17
- 235000018102 proteins Nutrition 0.000 description 15
- 108020004635 Complementary DNA Proteins 0.000 description 12
- 230000001086 cytosolic effect Effects 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 210000001744 T-lymphocyte Anatomy 0.000 description 9
- 239000000523 sample Substances 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 238000010561 standard procedure Methods 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 description 6
- 239000012228 culture supernatant Substances 0.000 description 6
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000008279 sol Substances 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000003412 degenerative effect Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 4
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 4
- 238000000636 Northern blotting Methods 0.000 description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 4
- 108091034057 RNA (poly(A)) Proteins 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000003656 tris buffered saline Substances 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 3
- 102000000844 Cell Surface Receptors Human genes 0.000 description 3
- 108010001857 Cell Surface Receptors Proteins 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 108010047620 Phytohemagglutinins Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000001885 phytohemagglutinin Effects 0.000 description 3
- 238000007747 plating Methods 0.000 description 3
- 210000001938 protoplast Anatomy 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- IORKCNUBHNIMKY-CIUDSAMLSA-N Ala-Pro-Glu Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O IORKCNUBHNIMKY-CIUDSAMLSA-N 0.000 description 2
- 241000701822 Bovine papillomavirus Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 230000004988 N-glycosylation Effects 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000010382 chemical cross-linking Methods 0.000 description 2
- 102000003675 cytokine receptors Human genes 0.000 description 2
- 108010057085 cytokine receptors Proteins 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 102000055277 human IL2 Human genes 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 238000003118 sandwich ELISA Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 101710181478 Envelope glycoprotein GP350 Proteins 0.000 description 1
- 241001288713 Escherichia coli MC1061 Species 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- BQSLGJHIAGOZCD-CIUDSAMLSA-N Leu-Ala-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O BQSLGJHIAGOZCD-CIUDSAMLSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 101001043827 Mus musculus Interleukin-2 Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 150000001510 aspartic acids Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000001400 expression cloning Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 150000002307 glutamic acids Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP89104023A EP0386289A1 (fr) | 1989-03-07 | 1989-03-07 | Récepteur d'interleukine-2 recombinant |
| EP89109656A EP0386304A1 (fr) | 1989-03-07 | 1989-05-29 | Récepteur d'interleukine-2 recombinant |
| EP89113310A EP0408790A1 (fr) | 1989-07-20 | 1989-07-20 | Récepteur protéique recombinant |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO901046D0 NO901046D0 (no) | 1990-03-06 |
| NO901046L NO901046L (no) | 1990-09-10 |
| NO306624B1 true NO306624B1 (no) | 1999-11-29 |
Family
ID=27232332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO901046A NO306624B1 (no) | 1989-03-07 | 1990-03-06 | Rekombinant DNA-molekyl som koder for <beta>-kjeden til en IL-2 reseptor |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US5198359A (fr) |
| EP (1) | EP0395853B1 (fr) |
| JP (1) | JP3339855B2 (fr) |
| AT (1) | ATE166921T1 (fr) |
| AU (1) | AU639226B2 (fr) |
| CA (1) | CA2011450C (fr) |
| DE (1) | DE69032357T2 (fr) |
| DK (1) | DK0395853T3 (fr) |
| ES (1) | ES2117623T3 (fr) |
| FI (1) | FI104188B1 (fr) |
| HU (1) | HUT57827A (fr) |
| IE (1) | IE81125B1 (fr) |
| IL (1) | IL93660A (fr) |
| NO (1) | NO306624B1 (fr) |
| NZ (1) | NZ232832A (fr) |
| PT (1) | PT93345B (fr) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1341588C (fr) * | 1988-01-26 | 2009-01-06 | Michel Revel | Ifn-beta2/i1-6, humain, sa purification et ses utilisations |
| US20040049014A1 (en) * | 1988-12-28 | 2004-03-11 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| JP3024311B2 (ja) * | 1991-10-03 | 2000-03-21 | 味の素株式会社 | Ｉｌ−２受容体重鎖に結合するポリペプチド |
| US6824777B1 (en) * | 1992-10-09 | 2004-11-30 | Licentia Ltd. | Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy |
| US5776755A (en) * | 1992-10-09 | 1998-07-07 | Helsinki University Licensing, Ltd. | FLT4, a receptor tyrosine kinase |
| US6107046A (en) * | 1992-10-09 | 2000-08-22 | Orion Corporation | Antibodies to Flt4, a receptor tyrosine kinase and uses thereof |
| US5536657A (en) * | 1993-07-19 | 1996-07-16 | Hoffmann-La Roche Inc. | Recombinant DNA encoding human receptor for interleukin-12 |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US5650295A (en) * | 1995-06-02 | 1997-07-22 | Human Genone Sciences, Inc. | Macrophage migration inhibitory factor-3 |
| US5635597A (en) * | 1994-05-27 | 1997-06-03 | Affymax Technologies, N.V. | Peptides that bind IL-2 receptors |
| EP0804578B1 (fr) * | 1995-01-09 | 2008-07-16 | Boehringer Ingelheim International GmbH | Polypeptide associe a il-2r et molecules d'adn codant pour celui-ci |
| TW555765B (en) | 1996-07-09 | 2003-10-01 | Amgen Inc | Low molecular weight soluble tumor necrosis factor type-I and type-II proteins |
| CN100340291C (zh) * | 1998-10-09 | 2007-10-03 | 路德维格癌症研究院 | F1t4(VEGFR－3)作为肿瘤显像和抗肿瘤治疗的靶 |
| JP2003523179A (ja) * | 1999-11-18 | 2003-08-05 | シェーリング コーポレイション | 哺乳動物レセプタータンパク質；関連する試薬および方法 |
| AU2002248372B8 (en) | 2001-01-19 | 2008-03-20 | Vegenics Limited | FLT4(VEGFR-3) as a target for tumor imaging and anti-tumor therapy |
| US7175988B2 (en) * | 2001-02-09 | 2007-02-13 | Human Genome Sciences, Inc. | Human G-protein Chemokine Receptor (CCR5) HDGNR10 |
| DE60238095D1 (de) | 2001-04-20 | 2010-12-09 | Yazaki Corp | Ausschaltvorrichtung |
| US20060147945A1 (en) * | 2005-01-06 | 2006-07-06 | Edmonds Brian T | Novel secreted proteins and their uses |
| US20080283557A1 (en) * | 2007-05-17 | 2008-11-20 | Julianne Desautels | Spout for food stuff container |
| WO2009086624A1 (fr) * | 2008-01-04 | 2009-07-16 | The Royal Institution For The Advancement Of Learning/Mcgill University | Système de micromatrice microfluidique et procédé destinés à l'analyse multiplexée de biomolécules |
| EP4069725A4 (fr) * | 2019-12-05 | 2024-01-10 | Immune Targeting Inc. | Protéines de fusion de l'interleukine 15 et promédicaments, ainsi que compositions et procédés associés |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1339269C (fr) * | 1984-05-21 | 1997-08-12 | Douglas P. Cerretti | Purification et clonage du gene pour le recepteur de l'interleukine-2 |
| US4707443A (en) * | 1985-04-19 | 1987-11-17 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Soluble interleukin-2 receptor as a disease indicator and a method of assaying the same |
| AU1992388A (en) * | 1987-06-29 | 1989-01-30 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Novel interleukin-2 receptor and applications thereof |
-
1990
- 1990-03-05 CA CA002011450A patent/CA2011450C/fr not_active Expired - Lifetime
- 1990-03-05 US US07/487,059 patent/US5198359A/en not_active Expired - Lifetime
- 1990-03-06 AU AU50726/90A patent/AU639226B2/en not_active Expired
- 1990-03-06 AT AT90104246T patent/ATE166921T1/de not_active IP Right Cessation
- 1990-03-06 HU HU901326A patent/HUT57827A/hu unknown
- 1990-03-06 EP EP90104246A patent/EP0395853B1/fr not_active Expired - Lifetime
- 1990-03-06 JP JP05483190A patent/JP3339855B2/ja not_active Expired - Lifetime
- 1990-03-06 PT PT93345A patent/PT93345B/pt not_active IP Right Cessation
- 1990-03-06 ES ES90104246T patent/ES2117623T3/es not_active Expired - Lifetime
- 1990-03-06 NO NO901046A patent/NO306624B1/no not_active IP Right Cessation
- 1990-03-06 IE IE79390A patent/IE81125B1/en not_active IP Right Cessation
- 1990-03-06 DK DK90104246T patent/DK0395853T3/da active
- 1990-03-06 FI FI901124A patent/FI104188B1/fi active IP Right Grant
- 1990-03-06 DE DE69032357T patent/DE69032357T2/de not_active Expired - Lifetime
- 1990-03-06 IL IL9366090A patent/IL93660A/en not_active IP Right Cessation
- 1990-03-07 NZ NZ232832A patent/NZ232832A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0367588A (ja) | 1991-03-22 |
| DE69032357T2 (de) | 1998-10-29 |
| HUT57827A (en) | 1991-12-30 |
| EP0395853B1 (fr) | 1998-06-03 |
| PT93345A (pt) | 1990-11-07 |
| US5198359A (en) | 1993-03-30 |
| NZ232832A (en) | 1991-11-26 |
| ES2117623T3 (es) | 1998-08-16 |
| ATE166921T1 (de) | 1998-06-15 |
| NO901046D0 (no) | 1990-03-06 |
| EP0395853A1 (fr) | 1990-11-07 |
| IE900793L (en) | 1990-09-07 |
| IE81125B1 (en) | 2000-03-22 |
| AU5072690A (en) | 1990-09-13 |
| PT93345B (pt) | 1996-02-29 |
| JP3339855B2 (ja) | 2002-10-28 |
| AU639226B2 (en) | 1993-07-22 |
| DE69032357D1 (de) | 1998-07-09 |
| FI104188B (fi) | 1999-11-30 |
| NO901046L (no) | 1990-09-10 |
| IL93660A0 (en) | 1990-12-23 |
| FI901124A0 (fi) | 1990-03-06 |
| IL93660A (en) | 2001-11-25 |
| FI104188B1 (fi) | 1999-11-30 |
| HU901326D0 (en) | 1990-05-28 |
| CA2011450C (fr) | 2002-06-04 |
| DK0395853T3 (da) | 1999-02-15 |
| CA2011450A1 (fr) | 1990-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0395853B1 (fr) | Récepteur d'interleukine-2 recombinant | |
| Hatakeyama et al. | Interleukin-2 receptor β chain gene: generation of three receptor forms by cloned human α and β chain cDNA's | |
| Cosman et al. | A new cytokine receptor superfamily | |
| Raines et al. | Identification and molecular cloning of a soluble human granulocyte-macrophage colony-stimulating factor receptor. | |
| Park et al. | Cloning of the murine thymic stromal lymphopoietin (TSLP) receptor: Formation of a functional heteromeric complex requires interleukin 7 receptor | |
| EP0760857B9 (fr) | Recepteur de l'oncostatine m | |
| AU651596B2 (en) | Type II interleukin-1 receptors | |
| Ishizaka-Ikeda et al. | Signal transduction mediated by growth hormone receptor and its chimeric molecules with the granulocyte colony-stimulating factor receptor. | |
| WO1990008822A1 (fr) | Recepteur d'erythropoietine | |
| NO328197B1 (no) | Anvendelse av en probe, anvendelse av en sekvens og fremgangsmate for in vitro diagnose. | |
| WO1994022914A1 (fr) | Recepteurs de cytokine chimeriques dans des lymphocytes | |
| Bamford et al. | IL‐15: the role of translational regulation in their expression | |
| Floss et al. | Naturally occurring and synthetic constitutive-active cytokine receptors in disease and therapy | |
| Mori et al. | Signal transduction by interleukin 2 receptor β chain: importance of the structural integrity as revealed by site-directed mutagenesis and generation of chimeric receptors | |
| KR0172123B1 (ko) | 재조합 단백질 수용체 | |
| EP0386289A1 (fr) | Récepteur d'interleukine-2 recombinant | |
| EP0408790A1 (fr) | Récepteur protéique recombinant | |
| Taniguchi et al. | Interleukin-2 Receptor β Chain: Molecular Cloning and Functional Expression of the Human cDNA | |
| Taga et al. | Interleukin-6 receptor and a unique mechanism of its signal transduction | |
| WO1994028130A1 (fr) | Gene codant un polypeptide capable de stimuler la proliferation des cellules pre-b | |
| Jones et al. | PEPTIDE INSERTIONS IN DOMAIN 4 OF hβc, THE SHARED SIGNALLING RECEPTOR SUBUNIT FOR GM-CSF, IL3 AND IL5, INDUCE LIGAND-INDEPENDENT ACTIVATION | |
| Urdal | Cytokine receptors | |
| 森寿 | Signal transduction by interleukin 2 receptor β | |
| Beckmann et al. | The amino acid sequences of several, recently cloned cytokine receptors show significant homologies, primarily in their extracellular, ligand-binding domains. With one exception, their cognate cytokines mediate biological activities on a variety of hematopoietic cell types; thus we have designated the receptors as the hematopoietin receptor superfamily. | |
| Ronco | A structural analysis of the human granulocyte-macrophage colony-stimulating factor receptor binding subunit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |